Raymond James & Associates’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Raymond James & Associates’s Portfolio RXII Stock Details RXII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-10,500	Closed	-$4K	–	3464
2016 Q3	$4K	Hold	10,500	–	–	﹤0.01%	3194
2016 Q2	$5K	Sell	10,500 -3,585	-25%	-$1.71K	﹤0.01%	2995
2016 Q1	$19K	Buy	+14,085	New	+$19K	﹤0.01%	2864

Raymond James & Associates's RXII Position: Q4 2016 in Review

Raymond James & Associates sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 10,500 shares — an estimated $4K sold.

Raymond James & Associates first reported a position in RXII in Q1 2016 and held it in 3 quarters. The position peaked at $19K in Q1 2016. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

Raymond James & Associates reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
Raymond James & Associates sold 10,500 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $4K.
Raymond James & Associates first reported a position in GALENA BIOPHARMA INC COM in Q1 2016 and held it in 3 quarters.
Raymond James & Associates's GALENA BIOPHARMA INC COM position peaked at $19K in Q1 2016.
0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.